Literature DB >> 28887643

Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study.

J Torre-Cisneros1,2, C Natera1,2, F Mesa3, M Trikic4, J Rodríguez-Baño2,5,6.   

Abstract

The situations in which coverage for methicillin-resistant Staphylococcus aureus (MRSA) in the empirical treatment of nosocomial pneumonia (NP) or severe healthcare-associated pneumonia (HCAP) is needed are poorly defined, particularly outside intensive care units (ICUs). Our aim was to characterize if the risk of MRSA NP/HCAP can be defined by clinical variables. We designed an observational, retrospective, multicenter, case-control study to analyze the association between defined clinical variables and risk of MRSA NP/HCAP in non-ICU patients using conditional multivariable logistic regression. Cases and controls (1:2) with microbiological diagnosis were included. Controls were matched for hospital, type of pneumonia (NP or HCAP), and date of isolation. A total of 140 cases (77 NP and 63 HCAP) and 280 controls were studied. The variables associated with the risk of MRSA pneumonia were: (i) respiratory infection/colonization caused by MRSA in the previous year [odds ratio (OR) 14.81, 95% confidence interval (CI) 4.13-53.13, p < 0.001]; (ii) hospitalization in the previous 90 days (OR 2.41, 95% CI 1.21-4.81, p = 0.012); and (iii) age (OR 1.02, 95% CI 1.001-1.05, p = 0.040). The area under the receiver operating characteristic (ROC) curve for the multivariable model was 0.72 (95% CI 0.66-0.78). The multivariate model had a sensitivity of 74.5% (95% CI 65.3-83.6), a specificity of 63.3% (95% CI 56.0-70.6), a positive predictive value of 52.5% (95% CI 43.9-61.2), and a negative predictive value of 82.0% (95% CI 75.3-88.8) for the observed data. Clinical predictors of MRSA NP/HCAP can be used to define a low-risk population in whom coverage against MRSA may not be needed.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28887643     DOI: 10.1007/s10096-017-3100-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Antibiotic treatment against methicillin-resistant Staphylococcus aureus hospital- and ventilator-acquired pneumonia: a step forward but the battle continues.

Authors:  Antoni Torres
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

Review 2.  Rethinking the concepts of community-acquired and health-care-associated pneumonia.

Authors:  Santiago Ewig; Tobias Welte; Jean Chastre; Antoni Torres
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

3.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

4.  Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective.

Authors:  Stefano Aliberti; Catia Cilloniz; James D Chalmers; Anna Maria Zanaboni; Roberto Cosentini; Paolo Tarsia; Alberto Pesci; Francesco Blasi; Antoni Torres
Journal:  Thorax       Date:  2013-06-17       Impact factor: 9.139

Review 5.  Pneumonia caused by methicillin-resistant Staphylococcus aureus.

Authors:  Ethan Rubinstein; Marin H Kollef; Dilip Nathwani
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

6.  Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study.

Authors:  Richard G Wunderink; Michael S Niederman; Marin H Kollef; Andrew F Shorr; Mark J Kunkel; Alice Baruch; William T McGee; Arlene Reisman; Jean Chastre
Journal:  Clin Infect Dis       Date:  2012-01-12       Impact factor: 9.079

7.  Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.

Authors:  Andrew F Shorr; Marya D Zilberberg; Richard Reichley; Jason Kan; Alex Hoban; Justin Hoffman; Scott T Micek; Marin H Kollef
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

Review 8.  Impact of Gram-positive resistance on outcome of nosocomial pneumonia.

Authors:  M Bodi ; C Ardanuy ; J Rello
Journal:  Crit Care Med       Date:  2001-04       Impact factor: 7.598

9.  Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.

Authors:  Yuichiro Shindo; Ryota Ito; Daisuke Kobayashi; Masahiko Ando; Motoshi Ichikawa; Akira Shiraki; Yasuhiro Goto; Yasutaka Fukui; Mai Iwaki; Junya Okumura; Ikuo Yamaguchi; Tetsuya Yagi; Yoshimasa Tanikawa; Yasuteru Sugino; Joe Shindoh; Tomohiko Ogasawara; Fumio Nomura; Hideo Saka; Masashi Yamamoto; Hiroyuki Taniguchi; Ryujiro Suzuki; Hiroshi Saito; Takashi Kawamura; Yoshinori Hasegawa
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

10.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

View more
  4 in total

1.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.

Authors:  Laura Evans; Andrew Rhodes; Waleed Alhazzani; Massimo Antonelli; Craig M Coopersmith; Craig French; Flávia R Machado; Lauralyn Mcintyre; Marlies Ostermann; Hallie C Prescott; Christa Schorr; Steven Simpson; W Joost Wiersinga; Fayez Alshamsi; Derek C Angus; Yaseen Arabi; Luciano Azevedo; Richard Beale; Gregory Beilman; Emilie Belley-Cote; Lisa Burry; Maurizio Cecconi; John Centofanti; Angel Coz Yataco; Jan De Waele; R Phillip Dellinger; Kent Doi; Bin Du; Elisa Estenssoro; Ricard Ferrer; Charles Gomersall; Carol Hodgson; Morten Hylander Møller; Theodore Iwashyna; Shevin Jacob; Ruth Kleinpell; Michael Klompas; Younsuck Koh; Anand Kumar; Arthur Kwizera; Suzana Lobo; Henry Masur; Steven McGloughlin; Sangeeta Mehta; Yatin Mehta; Mervyn Mer; Mark Nunnally; Simon Oczkowski; Tiffany Osborn; Elizabeth Papathanassoglou; Anders Perner; Michael Puskarich; Jason Roberts; William Schweickert; Maureen Seckel; Jonathan Sevransky; Charles L Sprung; Tobias Welte; Janice Zimmerman; Mitchell Levy
Journal:  Intensive Care Med       Date:  2021-10-02       Impact factor: 17.440

2.  Validation of Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Factors in Predicting MRSA Community-Acquired Pneumonia at an Academic Medical Center.

Authors:  Joelle Arieno; Robert Seabury; Wesley Kufel; William Darko; Christopher D Miller; William Paolo; Gregory Cwikla; Scott Riddell; Luke A Probst; Jeffrey M Steele
Journal:  Hosp Pharm       Date:  2021-04-24

Review 3.  Update of the treatment of nosocomial pneumonia in the ICU.

Authors:  Rafael Zaragoza; Pablo Vidal-Cortés; Gerardo Aguilar; Marcio Borges; Emili Diaz; Ricard Ferrer; Emilio Maseda; Mercedes Nieto; Francisco Xavier Nuvials; Paula Ramirez; Alejandro Rodriguez; Cruz Soriano; Javier Veganzones; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2020-06-29       Impact factor: 9.097

4.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.